Lakefront Biotherapeutics (LKFT) Interest Expenses (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Interest Expenses for 11 consecutive years, with -$160392.2 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 80.45% year-over-year to -$160392.2; the TTM figure through Mar 2026 stood at $1.3 million (up 109.21% YoY), while the FY2025 annual figure was $1.2 million, up 23.5% from the prior year.
• Interest Expenses slipped to -$160392.2 in Q1 2026 per LKFT's latest filing, from $3.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $26.1 million in Q4 2022 and bottomed at -$4.7 million in Q1 2022.
• Historically, Interest Expenses has averaged $1.7 million across 5 years, with a median of -$160392.2 in 2026.
• On a YoY basis, Interest Expenses climbed as much as 122.0% in 2025 and fell as far as 328.19% in 2025.
• Lakefront Biotherapeutics' Interest Expenses stood at $26.1 million in 2022, then tumbled by 88.33% to $3.0 million in 2023, then tumbled by 47.18% to $1.6 million in 2024, then surged by 122.0% to $3.6 million in 2025, then plunged by 104.5% to -$160392.2 in 2026.
• Business Quant data shows LKFT's Interest Expenses at -$160392.2 in Q1 2026, $3.6 million in Q4 2025, and -$2.7 million in Q3 2025.